PharmaEssentia Corp.
ent_1c5edb32438668d6fab9b58c
Disclosures
2
Leak Site · 1 jurisdiction
Multi-filing incidents
—
no multi-filing incident in sample
Max affected reported
—
no filed count in sample
Leak-site claims
2
unverified actor claims
Identity resolution
- Canonical name
- PharmaEssentia Corp.
- Normalized
- pharmaessentia— dedupe via name-norm; Microsoft / MSFT collapse to one row
- GLEIF LEI
- No match
- SEC EDGAR CIK
- None — not an SEC registrant
- Domain
- pharmaessentia.com
Unverified threat-actor claim — not a regulatory filing
Attribution, victim identity, and counts shown here derive from a threat actor's public extortion-blog claims, aggregated by ransomware.live. They have not been validated by the victim or any regulator. Treat them as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.
Disclosure history (2)newest first
- GLOBALLeak Siteas victim2026-09-09
pharmaessentia.com zoominfo.com/c/pharmaessentia-corp/145441146 PharmaEssentia Taiwanese global biopharma founded in 2003, known for besremi® (ropeginterferon alfa-2b) — the first drug developed in Taiwan ever approved by the FDA (2021) and the only polycythemia vera (PV) therapy approved in both the US and EU. Its innovation: a mono-pegylated long-acting interferon dosed every 2 weeks at home, with disease-modifying potential (reducing JAK2V617F mutant allele frequency) — a premium rare-disease asset vs. hydroxyurea and Jakafi. Financials: $197M+ revenue in 2024 (~89% gross margin), TPEX-listed (6446) with a ~5x stock rally since 2024; next bets: essential thrombocythemia (ET) Phase 3 and myelofibrosis. Bottom line: the Taiwanese biotech that proved a local startup can take a molecule from out-license to FDA approval and global commercialization — a rare-disease champion with an expanding moat.
- GLOBALLeak Siteas victim2026-08-09
pharmaessentia.com zoominfo.com/c/pharmaessentia-corp/145441146 PharmaEssentia is a global biopharmaceutical innovator founded in 2003 and headquartered in Taiwan. It specializes in developing best-in-class therapies and biologics for blood disorders, hematologic cancers, and other serious diseases. The company is fully integrated and operates internationally with a strong commercial and clinical presence in the U.S., Europe, and Japan.